Skip to content

Diagnostic value of heparin-binding protein combined with procalcitonin in pancreaticospecific complications after pancreaticoduodenectomy

Diagnostic value of heparin-binding protein combined with procalcitonin in pancreaticospecific complications after pancreaticoduodenectomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071621
Enrollment
Unknown
Registered
2023-05-19
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

specific complications after pancreaticoduodenectomy (PD)

Interventions

observation group:N/A

Sponsors

Guangdong Provincial People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age : =18 years old 2) patients with a diagnosis of pancreatic ductal adenocarcinoma 3) Patients volunteered to participate in this study, signed written informed consent, and were willing to cooperate with follow-up 4) patients undergoing pancreaticoduodenectomy

Exclusion criteria

Exclusion criteria: 1) patients who underwent any surgery within 4 weeks before the examination; 2) patients' ALT) or AST was greater than or equal to 1.5 times the upper limit of normal value, or CCr was greater than the upper limit of normal value; 3) The patients' WBC was greater than 10.0X109/L or less than 1.0X09/L at the time of screening examination; 4) the patient has a history of immunodeficiency diseases (e.g. HIV), or a history of cancer or malignancy other than pancreatic cancer, or a history of autoimmune diseases, or serious cardiovascular or cerebrovascular diseases, or other diseases that may significantly reduce life expectancy; 5) a history of any medical conditions (e.g. severe mental disorders, cognitive impairment, substance abuse or addiction) that may affect adherence to the protocol; 6) severe anemia patients with hemoglobin < 7g before surgery; 7) enrolled in a clinical trial within 6 months before screening; 8) patients judged by the investigator to be ineligible for the study;

Design outcomes

Primary

MeasureTime frame
heparin-binding protein combined with procalcitonin;Pancreatic specific complications;

Secondary

MeasureTime frame
hospital stay;Postoperative outcome;Complications (bleeding, delayed gastric emptying, intestinal obstruction, etc.);

Countries

China

Contacts

Public ContactShu Haihua

Department of Anesthesiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University

shuhaihua@hotmail.com+86 134 2753 6899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026